Kaleido Biosciences, Inc.
Kaleido Biosciences, Inc.
Your view on KLDO
Overview
What the company does, where it operates, and who runs it.
About Kaleido Biosciences, Inc.
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Mark A. Wingertzahn
- Headquarters
- 65 Hayden Avenue, Lexington, MA, US
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Mark A. Wingertzahn
- Headquarters
- 65 Hayden Avenue, Lexington, MA, US
Kaleido Biosciences, Inc., a clinical-stage healthcare company, develops microbiome metabolic therapies. The company develops KB195 for the treatment of patients with urea cycle disorder; KB295 to treat ulcerative colitis; KB174 for the treatment of hepatic encephalopathy; and KB109 to treat COVID-19 disease.
It also develops programs for the treatment of multi drug resistant infection, chronic kidney disease, atherosclerotic cardiovascular disease, cardio-metabolic syndrome, immuno-oncology, and inflammatory bowel diseases. The company has collaboration agreements with Institute Gustave Roussy, Washington University, and Janssen.
Kaleido Biosciences, Inc. was incorporated in 2015 and is headquartered in Lexington, Massachusetts.
Media
Infographics, videos, and posts covering the company.
Stock Data
Price chart, volume, and trading data.
Fair Value
What FRC thinks it is worth vs. the current price.
FRC's fair value estimate for Kaleido Biosciences, Inc., and the rating behind it. KLDO last traded at $0.0001; the estimate is read against that market price. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Valuation, profitability, liquidity and leverage ratios for Kaleido Biosciences, Inc.. Starting points for Kaleido Biosciences, Inc.: EPS -$2.16, beta -1.17 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Dividend history, yield and payout sustainability for Kaleido Biosciences, Inc.. Kaleido Biosciences, Inc. does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Reported vs. expected earnings history for Kaleido Biosciences, Inc.. Trailing twelve-month EPS for Kaleido Biosciences, Inc. stands at -$2.16. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
Income statement, balance sheet and cash flow history for Kaleido Biosciences, Inc.. Kaleido Biosciences, Inc. has reported as a listed company since 2019. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
Kaleido Biosciences, Inc. valued side by side against its closest peers. Kaleido Biosciences, Inc. is measured against Biotechnology peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.
Institutional Ownership
PremiumWhich funds and firms own the stock.
Which institutions hold Kaleido Biosciences, Inc., and how their positions are changing. At a $4,262 market value, institutional positions materially move Kaleido Biosciences, Inc.'s register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings. Included with FRC Premium.
Insider Trading
PremiumRecent buying and selling by company executives.
Buying and selling by Kaleido Biosciences, Inc. executives and directors. Shares of Kaleido Biosciences, Inc. have traded between $0.0000 and $0.19 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned. Included with FRC Premium.
Senate Trading
PremiumU.S. Senator disclosures filed under the STOCK Act.
U.S. Senate disclosures naming Kaleido Biosciences, Inc.. Kaleido Biosciences, Inc. is a $4,262 Healthcare company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely. Included with FRC Premium.
House Trading
PremiumU.S. Representative disclosures filed under the STOCK Act.
U.S. House of Representatives disclosures naming Kaleido Biosciences, Inc.. Representatives' reported transactions in this security, shown next to the company's fundamentals. Included with FRC Premium.
News
Latest headlines and market coverage.
Latest headlines and company announcements for Kaleido Biosciences, Inc.. Coverage tracks Kaleido Biosciences, Inc. within Biotechnology (Healthcare). Press releases and market coverage, newest first.